Vergent Bioscience Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series C
- (In Progress)
- Latest Deal Amount
-
$20M
- Investors
-
7
Vergent Bioscience General Information
Description
Developer of molecular imaging technology designed to detect cancerous tissue during surgery. The company offers tumor-activated imaging agents that identify malignant tissue not visible under conventional lighting, enabling surgeons to locate tumors and guide tissue removal during minimally invasive and robotic cancer procedures.
Contact Information
Website
www.vergentbio.comCorporate Office
- 5810 West 78th Street
- Suite 222
- Minneapolis, MN 55439
- United States
Corporate Office
- 5810 West 78th Street
- Suite 222
- Minneapolis, MN 55439
- United States
Vergent Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 07-Oct-2025 | $20M | In Progress | Clinical Trials - Phase 3 | ||
| 4. Mezzanine | 18-Feb-2025 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC (Series B) | 04-Oct-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 08-Sep-2022 | $7.11M | $11.9M | Completed | Clinical Trials - Phase 1 | |
| 1. Later Stage VC (Series A) | 23-Sep-2020 | $11.9M | $11.9M | Completed | Pre-Clinical Trials |
Vergent Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-2 | ||||||||
| Series C-1 | ||||||||
| Series B | ||||||||
| Series A | 28,530,868 | $0.000100 | $0.04 | $0.44 | $0.44 | 1x | $0.44 | 22.78% |
| Founders | 7,000,000 | $0.000100 | $0.03 | $0.65 | $0.65 | 1x | $0.65 | 5.59% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Vergent Bioscience Comparisons
Industry
Financing
Details
Vergent Bioscience Competitors (18)
One of Vergent Bioscience’s 18 competitors is Cytosorbents, a Corporation company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cytosorbents | Corporation | Princeton, NJ | ||||
| Epic Sciences | Venture Capital-Backed | San Diego, CA | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| GeneCast Biotechnology | Private Equity-Backed | Wuxi, China | ||||
| RareCyte | Venture Capital-Backed | Seattle, WA |
Vergent Bioscience Patents
Vergent Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023215269-A1 | Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment | Active | 02-Feb-2022 | ||
| AU-2023215269-B2 | Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment | Active | 02-Feb-2022 | ||
| AU-2026223208-A1 | Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment | Pending | 02-Feb-2022 | ||
| EP-4472485-A1 | Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment | Pending | 02-Feb-2022 | ||
| EP-4472485-A4 | Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment | Pending | 02-Feb-2022 | A61B1/2676 |
Vergent Bioscience Signals
Vergent Bioscience Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Intuitive | Corporation | Minority | ||
| Orlando Health Ventures | Corporate Venture Capital | Minority | ||
| UNC Health Ventures | Corporate Venture Capital | Minority | ||
| Windham Capital Partners | Venture Capital | Minority | ||
| National Institutes of Health | Government |
Vergent Bioscience FAQs
-
When was Vergent Bioscience founded?
Vergent Bioscience was founded in 2013.
-
Where is Vergent Bioscience headquartered?
Vergent Bioscience is headquartered in Minneapolis, MN.
-
What is the size of Vergent Bioscience?
Vergent Bioscience has 10 total employees.
-
What industry is Vergent Bioscience in?
Vergent Bioscience’s primary industry is Biotechnology.
-
Is Vergent Bioscience a private or public company?
Vergent Bioscience is a Private company.
-
What is the current valuation of Vergent Bioscience?
The current valuation of Vergent Bioscience is .
-
What is Vergent Bioscience’s current revenue?
The current revenue for Vergent Bioscience is .
-
How much funding has Vergent Bioscience raised over time?
Vergent Bioscience has raised $37.8M.
-
Who are Vergent Bioscience’s investors?
Intuitive, Orlando Health Ventures, UNC Health Ventures, Windham Capital Partners, and National Institutes of Health are 5 of 7 investors who have invested in Vergent Bioscience.
-
Who are Vergent Bioscience’s competitors?
Cytosorbents, Epic Sciences, TScan Therapeutics, GeneCast Biotechnology, and RareCyte are some of the 18 competitors of Vergent Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process